Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuromuscular disease: acute treatment for myasthenia gravis.

Literature DB >> 21386868

Neuromuscular disease: acute treatment for myasthenia gravis.

Nils Erik Gilhus¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2011 PMID： 21386868 DOI： 10.1038/nrneurol.2011.14

Source DB: PubMed Journal: Nat Rev Neurol ISSN： 1759-4758 Impact factor: 42.937

× No keyword cloud information.

10 in total

1. The use of intravenous immunoglobulins in Belgium.

Authors: Steven Simoens
Journal: Int Arch Allergy Immunol Date: 2010-08-24 Impact factor: 2.749

2. Comparative analysis of therapeutic options used for myasthenia gravis.

Authors: Aditya Mandawat; Henry J Kaminski; Gary Cutter; Bashar Katirji; Amer Alshekhlee
Journal: Ann Neurol Date: 2010-12 Impact factor: 10.422

3. Causes and outcomes of acute neuromuscular respiratory failure.

Authors: Macarena Cabrera Serrano; Alejandro A Rabinstein
Journal: Arch Neurol Date: 2010-09

4. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

Authors: J F Owe; A K Daltveit; N E Gilhus
Journal: J Neurol Neurosurg Psychiatry Date: 2006-02 Impact factor: 10.154

5. Myasthenia gravis.

Authors: Agnes Jani-Acsadi; Robert P Lisak
Journal: Curr Treat Options Neurol Date: 2010-05 Impact factor: 3.598

6. Guidelines for treatment of autoimmune neuromuscular transmission disorders.

Authors: G O Skeie; S Apostolski; A Evoli; N E Gilhus; I Illa; L Harms; D Hilton-Jones; A Melms; J Verschuuren; H W Horge
Journal: Eur J Neurol Date: 2010-04-12 Impact factor: 6.089

Review 7. Autoimmune myasthenia gravis.

Authors: Nils Erik Gilhus
Journal: Expert Rev Neurother Date: 2009-03 Impact factor: 4.618

8. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors: I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal: Eur J Neurol Date: 2008-09 Impact factor: 6.089

9. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals.

Authors: A Alshekhlee; J D Miles; B Katirji; D C Preston; H J Kaminski
Journal: Neurology Date: 2009-05-05 Impact factor: 9.910

Review 10. Intravenous immunoglobulin for myasthenia gravis.

Authors: P Gajdos; S Chevret; K Toyka
Journal: Cochrane Database Syst Rev Date: 2008-01-23